MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtha.2025.10.020

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2025

Outcomes of anticoagulation treatment for renal cell carcinoma tumor thrombi: a systematic review.

Akerboom Bram, Martens Emily S L, Kaptein Fleur H J, Kondo Tsunenori, van der Hulle Tom, van Gennep Erik J, Versteeg Henri H, van Mens Thijs E, Klok Frederikus A

СтатьяСистематический обзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with renal cell carcinoma (RCC) and tumor thrombus (TT) are at significant risk of venous thromboembolism (VTE).

OBJECTIVES

This systematic review aimed to assess the role of anticoagulation in ambulatory patients with RCC and TT.

METHODS

Inclusion criteria were diagnosis of RCC with TT, reporting of VTE, major bleeding and/or arterial thromboembolism, as well as exposure to anticoagulation. Studies with <30 patients were excluded. Studies were also excluded if anticoagulation status was not reported per outcome stratum. A comprehensive search was conducted in PubMed and other databases. Risk of bias was assessed in accordance with the Scottish Intercollegiate Guidelines Network bias quality assessment tool.

RESULTS

Six observational studies containing 659 patients were included. All studies had considerable risk of bias. Anticoagulation use ranged from 3.9% to 50%. Two studies reported a lower VTE incidence in anticoagulated patients than in non-anticoagulated patients: 7.3% (1.2-21) vs 20% (6.9-37) after 1 year, and 18% (1.5-49) vs 24% (14-36) after 2 years. In anticoagulated patients, major bleeding incidence was 12% (2.8-27) after 1 year and 33% (8.2-60) after 2 years. For non-anticoagulated patients the incidence was 19% (6.6-36) after 1 year and 12% (5.1-22) after 2 years. Importantly, none of the studies were management studies, and confidence intervals of our outcomes were wide.

CONCLUSION

Anticoagulation in patients with RCC with TT may lower VTE risk. Bleeding risk is high in both anticoagulated as well as non-anticoagulated patients. Current evidence remains inconclusive due to study heterogeneity and risk of bias.

Для цитирования: Akerboom Bram, Martens Emily S L, Kaptein Fleur H J, Kondo Tsunenori, van der Hulle Tom, van Gennep Erik J, Versteeg Henri H, van Mens Thijs E, Klok Frederikus A. Outcomes of anticoagulation treatment for renal cell carcinoma tumor thrombi: a systematic review.. Journal of thrombosis and haemostasis : JTH. 2025. DOI: 10.1016/j.jtha.2025.10.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.